Clinical Trial Update: Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating parathyroid hormone and zoledronic acid for osteogenesis imperfecta has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteogenesis Imperfecta

Drugs mentioned

• Parathyroid hormone (Parathyroid hormone)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: University of Edinburgh | Conditions: Osteogenesis Imperfecta | Phase 4 | Status: COMPLETED